UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

EXHIBIT 99.1 Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022 Research & Development Highlights: Leadership & Governance: Financial: 2023 Outlook: ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built proteins known as DARPin therapeutics, today announced its corpor ...

Molecular Partners AG (NASDAQ:MOLN) Q2 2022 Earnings Conference Call August 25, 2022 8:00 AM ET Company Participants Seth Lewis - SVP of IR Patrick Amstutz - CEO Andreas Emmenegger - CFO Conference Call Participants Georgi Yordanov - Cowen and Company Richard Vosser - JPMorgan Daina Graybosch - SVB Securities Jo Walton - Credit Suisse Zoe Karamanoli - RBC Capital Markets Operator Good day, and welcome to the Molecular Partners Second Quarter 2022 Half Year Report. All participants will be in listen-only mod ...

| --- | --- | --- | --- | |---------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | H1 2022 Corporate Highlights and Financials | | | | | August 26 , 2022 | | | | | Molecular Partners AG, Switzerland (SIX: MOLN, NASDAQ: MOLN) | | | | 1 Disclaimer This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defi ...

Molecular Partners AG (NASDAQ:MOLN) Q4 2021 Earnings Conference Call March 16, 2022 8:00 AM ET Company Participants Seth Lewis - Head, Investor Relations Patrick Amstutz - Chief Executive Officer Andreas Emmenegger - Chief Financial Officer Conference Call Participants Richard Vosser - JPMorgan Georgi Yordanov - Cowen & Company Jo Walton - Credit Suisse Daina Graybosch - SVB Leerink Operator Good morning and thank you for standing by. Welcome to the Publication of Full Year Results 2021. [Operator Instructi ...

EXHIBIT 99.1 Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021 Research & Development Highlights: Leadership & Governance: Financial: ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built proteins known as DARPin therapeutics, today announced its corporate highlights ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

| --- | --- | --- | --- | |--------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | Custom Built Biology for Patients Credit Suisse Healthcare Conf. | | | | | March 2022 | | | | | Molecular Partners AG, Switzerland (SIX: MOLN, NASDAQ: MOLN) | | | | 1 Disclaimer This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements ...

| --- | --- | --- | --- | |-----------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Custom Built Biology for Patients 40th Annual JPM Healthcare Conf. January 2022 | | | | | Molecular Partners AG, Switzerland (SIX: MOLN, NASDAQ: MOLN) | | | | 1 Disclaimer This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements a ...